solvay_live243_p02a04 somEdito

104683
CAPA FB100 : HOW TO SUPPLY
A NEW PRODUCT INTO A BIG MARKET WHILE
OVERCOMING PRODUCTION LIMITATIONS
EVERYTHING IS REPLACEABLE
Our client manufactures biodegradable
packaging for food products using
polylactic acid and starch. They were looking
for an adhesive sheet to bind together
different materials and fulfil the required
conditions. They initially opted for a Dow
product but were not completely satisfied.
They then contacted Solvay. We proposed
our new CAPA FB 100. A sample was supplied
to the client, whose tests proved to be
conclusive. Several small deliveries allowed
the client to gain experience with the
behaviour of the product. Finally, Solvay
received an order for 15 tonnes. However,
the product was custom-made by Alkor
Draka. Bad luck, this supplier accepted to
produce 10 tonnes but then stopped its
production, which meant that we had to find
a new manufacturer. In February 2006,
Solvay concluded an agreement with
Standridge Color Corp, an American company
that already manufactured the end product
for our client. The transfer of know-how was
carefully controlled to protect Solvay’s
intellectual property. The new partner is
developing a pilot and is meeting the
demands of Solvay and of the client. The
demand is gradually increasing and currently
amounts to 1 000 tonnes per annum. The fact
that the manufacturer is American and
already involved in the process also brings
a whole series of appreciable advantages.
> Jeffrey Neidinger; Stewart Derbyshire; Henri Wautier.
> SBU CAPROLACTONES
104604
ACHIEVE A LEADERSHIP POSITION
AS A GMP MANUFACTURER
OF THERAPEUTIC OLIGONUCLEOTIDES
WINNING THE LEADERSHIP
Girindus is a manufacturer of chemical
and pharmaceutical specialties
and process-developer and has skills in the
production of oligonucleotides, active
compounds being deployed in the treatment
of diseases such as cancer, asthma, AIDS,
allergies, cardio-vascular problems and
in skin applications. The company is present
in Germany and in the United States with
140 employees, including 50 scientists
of doctorate level. These specialists augment
the research skills of Solvay, as Solvay holds
a stake of over 75% in Girindus A.G. The
project consists of developing a process that
avoids wasting time and money during
the synthesis phase of a new product.
A completely new approach has been
developed and registered (protected
by copyright) involving the use of specific
solvents, a complex and reliable activator
for the basic material, the rationalisation
of the reaction process in the synthesis
of the oligonucleotides and simplification
of the purification. A whole range
of improvements have been implemented,
including the use of cheaper raw materials
and the reduction in the consumption of
solvents, to improve the competitive position
on the market. The therapeutic market is
particularly buoyant and Girindus is now
uniquely placed to increase its production
capacity, thus remaining a credible
and competitive supplier.
> Ern Edmonds; Kathy Ackley; Raj Bandaru; Inga Gwose;
Andreas Hohlfeld; Meinolf Lange; Frintz Link; Andreas
Schoenberger.
> SBU MOLECULAR SOLUTIONS
New business
J U L Y 2 0 0 6
27